A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
The FDA accepted Praxis Precision Medicines' NDA for ulixacaltamide in essential tremor and set a Jan. 29, 2027 PDUFA date. The filing is backed by positive Phase 3 Essential3 data.
CervoMed presents new MRI data showing neflamapimod may reduce basal forebrain atrophy in dementia with Lewy bodies and finalizes Phase 3 trial design. The drug has also been selected for a UK-funded ALS platform trial, with first dosing expected by end of 2026.
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
Praxis Precision Medicines has submitted new drug applications for ulixacaltamide in essential tremor and relutrigine in rare epilepsies, both granted Breakthrough Therapy Designation. The company reported $926 million in cash as of December 31, 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06328114 |
Accelerating TMS for Cervical Dystonia |
ENROLLING_BY_INVITATION | NA |
| NCT06015672 |
Accelerated TMS for Focal Hand Dystonia |
ACTIVE_NOT_RECRUITING | NA |
| NCT05400512 |
Cognitive Enhancement in Depression (The COG-D Study) |
COMPLETED | NA |
| NCT04553198 |
Quantifying the Role of Sensory Systems Processing in Post-Stroke Walking Recovery |
COMPLETED | NA |
| NCT04147624 |
Reducing the Effects of Aging on Cognition With Therapeutic Intervention of an Oral Nutrient (REACTION): A Pilot Trial |
COMPLETED | PHASE2 |
| NCT04007913 |
Incorporating teleCBIT Into a Hospital-Based Tic Program |
COMPLETED | NA |
| NCT03697434 |
Acceptability of Palliative Care in Parkinson Disease Care |
COMPLETED | NA |
| NCT03115827 |
Norepinephrine-targeted Therapy for Action Control in Parkinson Disease |
COMPLETED | PHASE4 |
| NCT02598076 |
Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures |
COMPLETED | NA |
| NCT02268578 |
Efficacy of TDCS for Treating Working Memory Dysfunction and Depression in Temporal Lobe Epilepsy |
WITHDRAWN | PHASE1 |
